Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 1.00 |
| ▸ | HSD11B1 | P28845 | 5/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | NCF1 | P14598 | 1/20 | 0.55 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Piperazine SCHEMBL5324447 | 0.98 | EPHX2 (0.97) | EPHX2HSD11B1MAPTTSHRHTT | |
| Hydrochloric Acid SCHEMBL10319192 | 0.98 | EPHX2 (0.97) | EPHX2HSD11B1MAPTTSHRHTT | |
| SCHEMBL5356587 | 0.94 | EPHX2 (0.89) | EPHX2HSD11B1MAPTTSHRHTT | |
| SCHEMBL22668886 | 0.85 | EPHX2 (0.73) | EPHX2HSD11B1MAPTTSHRHTT | |
| SCHEMBL22669112 | 0.83 | EPHX2 (0.71) | EPHX2HSD11B1MAPTTSHRHTT | |
| SCHEMBL1366662 | 0.82 | EPHX2 (0.69) | EPHX2HSD11B1MAPTTSHRHTT | |
| SCHEMBL2420277 | 0.81 | EPHX2 (0.68) | EPHX2HSD11B1MAPTTSHRHTT | |
| SCHEMBL1375425 | 0.81 | EPHX2 (0.68) | EPHX2HSD11B1MAPTTSHRHTT | |
| SCHEMBL1375423 | 0.81 | EPHX2 (0.68) | EPHX2HSD11B1MAPTTSHRHTT | |
| SCHEMBL30582915 | 0.81 | EPHX2 (0.68) | EPHX2HSD11B1MAPTTSHRHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 336 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109979663-B | Corrosion-resistant flame-retardant wire and cable and preparation method thereof | 陕西正泰电缆有限公司 | 2023-09-26 | — | — | CN | claimed |
| CN-104046246-B | The chemical-mechanical planarization of tungsten-containing substrate | 气体产品与化学公司 | 2016-06-15 | — | — | CN | claimed |
| US-20140273458-A1 | Chemical Mechanical Planarization for Tungsten-Containing Substrates | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2014-09-18 | — | — | US | claimed |
| EP-2779217-A2 | Chemical mechanical planarization for tungsten-containing substrates | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2014-09-17 | — | — | EP | claimed |
| EP-1802605-A1 | IMIDAZOLE DERIVATIVES AS VANILLOID RECEPTOR LIGANDS | Amgen, Inc (US) | 2007-07-04 | — | — | EP | claimed |
| WO-2006044527-A1 | IMIDAZOLE DERIVATIVES AS VANILLOID RECEPTOR LIGANDS | AMGEN INC. (US) | 2006-04-27 | — | — | WO | claimed |
| EP-1204645-A2 | MELANOCORTIN-4 RECEPTOR BINDING COMPOUNDS AND METHODS OF USE THEREOF | Millennium Pharmaceuticals, Inc. (US) | 2002-05-15 | — | — | EP | claimed |
| WO-2001010842-A2 | MELANOCORTIN-4 RECEPTOR BINDING COMPOUNDS AND METHODS OF USE THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2001-02-15 | — | — | WO | claimed |
| US-12398130-B2 | Acid addition salts of piperazine derivatives | ASCENEURON SA (CH) | 2025-08-26 | — | — | US | disclosed |
| CN-119775261-A | Collagen 1 translation inhibitors and methods of use thereof | 艾尼莫生物科技公司 | 2025-04-08 | — | — | CN | disclosed |
| US-12187741-B2 | Glycosidase inhibitors | ASCENEURON SA (CH) | 2025-01-07 | — | — | US | disclosed |
| CN-115427404-B | Collagen 1 translation inhibitors and methods of use thereof | 艾尼莫生物科技公司 | 2024-12-13 | — | — | CN | disclosed |
| WO-2024165050-A1 | PROTEOLYSIS-TARGETING CHIMERA (PROTAC) COMPOUNDS AND USES THEREOF FIELD | AUBRAK THERAPEUTICS (CN) | 2024-08-15 | — | — | WO | disclosed |
| US-20240217978-A1 | COMPOUND AS ADENOSINE A2a RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2024-07-04 | — | — | US | disclosed |
| EP-0668276-A1 | 2-ALKOXY-5,6,7,8-TETRAHYDROQUINOXALINE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE THEREOF | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1995-08-23 | — | — | EP | disclosed |
| EP-0345808-B1 | 1-Indolylalkyl-4-(substituted-pyridinyl)piperazines | BRISTOL MYERS SQUIBB CO (US) | 1995-01-11 | — | — | EP | disclosed |
| US-4954502-A | Antidepressants | BRISTOL-MYERS SQUIBB COMPANY (US) | 1990-09-04 | — | — | US | disclosed |
| EP-0345808-A1 | 1-Indolylalkyl-4-(substituted-pyridinyl)piperazines | Bristol-Myers Squibb Company (US) | 1989-12-13 | — | — | EP | disclosed |
| US-4885299-A | TREATMENT OF ENERGY INSUFFICIENCY AND CEREBRAL AGING | ADIR ET CIE (FR) | 1989-12-05 | — | — | US | disclosed |
| US-4859700-A | 2-(2,3-dihydro-2-oxo-3-benzofuranyl)acetic acid compounds having antihypoxic and nootropic effects | ADIR ET CIE (FR) | 1989-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12187741-B2 | Glycosidase inhibitors | GAA, ENGASE, GBA3 | EPHX2 1743/4885HSD11B1 1280/4885MAPT 13/4885 |
| US-12398130-B2 | Acid addition salts of piperazine derivatives | DNPEP, GAA, SLC30A5 | EPHX2 1237/4885HSD11B1 1441/4885MAPT 3165/4885 |
| US-20240217978-A1 | COMPOUND AS ADENOSINE A2a RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | ADORA2A, ADORA1, ADORA2B | EPHX2 768/4885HSD11B1 1276/4885MAPT 4359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.